Merck & Co.
AbbVie CEO reveals why it passed on Daiichiās cancer drug
AbbVie CEO Rich Gonzalez has revealed the company’s stance on the recent ADC transaction involving Daiichi and Merck. Despite being ...
Daiichi and AstraZeneca expand ADC pipelines after Enhertu triumph
At the European Society for Medical Oncology (ESMO) Congress, Daiichi Sankyo made a significant impact by striking a $4 billion ...
Moderna, BioNTech face hurdles in cancer vaccine production after COVID success
Moderna and BioNTech, both navigating their post-COVID future while reimagining cancer treatments, have encountered manufacturing hurdles along their respective journeys. ...
Keytruda: Merckās breakthrough cancer drug with mixed results at ESMO
Merck & Co. made significant strides at this year’s European Society for Medical Oncology (ESMO) congress, presenting a series of ...
Merck Drops Two Cancer ADCs from Kelun Deal, Focuses on Daiichi Sankyo
Merck & Co. is refining its strategy in the realm of antibody-drug conjugates (ADCs). Shortly after a $4 billion acquisition ...
ESMO 2023: GSKās Jemperli beats Merckās Keytruda in lung cancer survival trial
In a groundbreaking clinical trial, GSK has achieved remarkable patient survival results with its PD-1 inhibitor, Jemperli, when compared to ...
Merck and Daiichi join forces to develop novel cancer drugs in $22B deal
In a strategic move, Merck & Co. has solidified its position in the thriving field of antibody-drug conjugates (ADCs) through ...
Keytruda approved by FDA for early-stage lung cancer surgery, with a twist
In a groundbreaking development, the FDA has granted approval for Merck’s Keytruda to be employed in a continuous immunotherapy regimen ...
Merckās Keytruda extends survival of early lung cancer patients in trial, awaits FDA approval
Merck & Co.’s Keytruda has achieved a groundbreaking milestone in the treatment landscape for early-stage non-small cell lung cancer (NSCLC), ...
Keytruda shows promise in bladder cancer trial, Merck says
Merck’s immunotherapy drug, Keytruda, continues to demonstrate success in the field of bladder cancer. After securing FDA approvals for use ...
Sanofi Joins Forces with Teva, Merck, and Roivant in $500M Deal for Bowel Disease Race
Sanofi is making significant financial moves in the pharmaceutical landscape. Just one day after sealing a $175 million vaccine deal, ...
Keytruda-Lenvima combo fails to improve survival in two lung cancer trials
Merck and Eisai’s collaborative effort with Keytruda and Lenvima faces yet another setback in their quest to combat cancer. Despite ...
Merck showcases new data on sotatercept for PAH, awaits FDA decision
Merck & Co. has unveiled new clinical data on sotatercept, reinforcing the drug candidate’s safety and efficacy in the treatment ...
